Literature DB >> 32367502

Prognostic Impact of Pancreatic Invasion in Duodenal Carcinoma: A Single-Center Experience.

Nobuhito Nitta1, Katsuhisa Ohgi2, Teiichi Sugiura1, Yukiyasu Okamura1, Takaaki Ito1, Yusuke Yamamoto1, Ryo Ashida1, Keiko Sasaki3, Katsuhiko Uesaka1.   

Abstract

BACKGROUND: The prognostic factors for duodenal carcinoma (DC) remain unclear because of its rarity. This study aimed to investigate the prognostic impact of pancreatic invasion (PI) on postoperative survival for patients with DC.
METHODS: This study retrospectively analyzed 86 patients with DC, including 18 patients with PI, who underwent surgical resection between October 2002 and March 2018. The clinicopathologic features and survival outcomes of these patients were investigated to identify the prognostic factors in DC. The long-term survival for the DC patients with PI was compared with that for the patients who underwent resection for resectable pancreatic head carcinoma (RPHC) during the same period.
RESULTS: The median survival time (MST) for the DC patients with PI was 25.7 months, which was significantly worse than for the patients with T2 or deeper DC without PI (p = 0.010). The multivariate analysis showed that the independent prognostic factors were PI (hazard ratio [HR] 7.59; p = 0.019) and lymph node metastasis (LNM) (HR 5.01; p = 0.026). The MST for the DC patients with PI did not differ significantly from that for the RPHC patients treated without adjuvant chemotherapy (p = 0.135). Comparable rates of microscopic venous invasion and hematogenous metastasis were observed for the DC patients with PI and the RPHC patients.
CONCLUSIONS: Pancreatic invasion was an independent prognostic factor in DC. The survival outcomes for the DC patients with PI did not differ from those for the patients with RPHC, which was associated with a high rate of hematogenous recurrence.

Entities:  

Mesh:

Year:  2020        PMID: 32367502     DOI: 10.1245/s10434-020-08512-8

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  36 in total

1.  Duodenal adenocarcinoma: clinicopathologic analysis and implications for treatment.

Authors:  George A Poultsides; Lyen C Huang; John L Cameron; Richard Tuli; Leslie Lan; Ralph H Hruban; Timothy M Pawlik; Joseph M Herman; Barish H Edil; Nita Ahuja; Michael A Choti; Christopher L Wolfgang; Richard D Schulick
Journal:  Ann Surg Oncol       Date:  2011-12-14       Impact factor: 5.344

2.  Incidence patterns of small bowel cancer in a population-based study in Sweden: increase in duodenal adenocarcinoma.

Authors:  Yunxia Lu; Robin Fröbom; Jesper Lagergren
Journal:  Cancer Epidemiol       Date:  2012-03-08       Impact factor: 2.984

3.  Extent of resection in the management of duodenal adenocarcinoma.

Authors:  I G Kaklamanos; O F Bathe; D Franceschi; C Camarda; J Levi; A S Livingstone
Journal:  Am J Surg       Date:  2000-01       Impact factor: 2.565

4.  A population-based comparison of adenocarcinoma of the large and small intestine: insights into a rare disease.

Authors:  Michael J Overman; Chung-Yuan Hu; Scott Kopetz; James L Abbruzzese; Robert A Wolff; George J Chang
Journal:  Ann Surg Oncol       Date:  2011-12-21       Impact factor: 5.344

5.  Outcome after surgical resection for duodenal adenocarcinoma in the UK.

Authors:  L Solaini; N B Jamieson; M Metcalfe; M Abu Hilal; Z Soonawalla; B R Davidson; C McKay; H M Kocher
Journal:  Br J Surg       Date:  2015-03-16       Impact factor: 6.939

6.  Results of pancreaticoduodenectomy in patients with periampullary adenocarcinoma: perineural growth more important prognostic factor than tumor localization.

Authors:  Margijske H G van Roest; Annette S H Gouw; Paul M J G Peeters; Robert J Porte; Maarten J H Slooff; Vaclav Fidler; Koert P de Jong
Journal:  Ann Surg       Date:  2008-07       Impact factor: 12.969

7.  2564 resected periampullary adenocarcinomas at a single institution: trends over three decades.

Authors:  Jin He; Nita Ahuja; Martin A Makary; John L Cameron; Frederic E Eckhauser; Michael A Choti; Ralph H Hruban; Timothy M Pawlik; Christopher L Wolfgang
Journal:  HPB (Oxford)       Date:  2013-03-08       Impact factor: 3.647

8.  Does the extent of resection impact survival for duodenal adenocarcinoma? Analysis of 1,611 cases.

Authors:  Jordan M Cloyd; Jeffrey A Norton; Brendan C Visser; George A Poultsides
Journal:  Ann Surg Oncol       Date:  2014-08-27       Impact factor: 5.344

9.  Prognostic factors and treatment outcomes in patients with Small Bowel Adenocarcinoma (SBA): the Royal Marsden Hospital (RMH) experience.

Authors:  Khurum Khan; Clare Peckitt; Francesco Sclafani; David Watkins; Sheela Rao; Naureen Starling; Vikram Jain; Sachin Trivedi; Susannah Stanway; David Cunningham; Ian Chau
Journal:  BMC Cancer       Date:  2015-01-21       Impact factor: 4.430

10.  Outcomes and Treatment Options for Duodenal Adenocarcinoma: A Systematic Review and Meta-Analysis.

Authors:  Laura L Meijer; Anna J Alberga; Jacob K de Bakker; Hans J van der Vliet; Tessa Y S Le Large; Nicole C T van Grieken; Ralph de Vries; Freek Daams; Barbara M Zonderhuis; Geert Kazemier
Journal:  Ann Surg Oncol       Date:  2018-06-26       Impact factor: 5.344

View more
  2 in total

1.  Segmental resection with partial mesopancreatic and mesojejunal excision (pMME) for duodenal carcinoma of the third or fourth portion.

Authors:  Ryota Ito; Yoshihiro Mise; Yu Takahashi; Yosuke Inoue; Fumihiro Kawano; Haruka Tanaka; Shoichi Irie; Hirofumi Ichida; Ryuji Yoshioka; Akio Saiura
Journal:  Langenbecks Arch Surg       Date:  2022-05-30       Impact factor: 2.895

2.  Surgical treatment of duodenal adenocarcinoma: ampullary vs. non-ampullary, short- and long-term outcomes.

Authors:  Jana Tesarikova; Pavel Skalicky; Daniela Kurfurstova; Hana Svebisova; Ondrej Urban; Premysl Falt; Jana Zapletalova; Dusan Klos; Martin Lovecek
Journal:  Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub       Date:  2021-05-11       Impact factor: 1.648

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.